drugset
drugset / Trial / NCT07114874

NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia

NCT07114874 ↗

Phase 3 Recruiting 600 enrolled Neurocrine Biosciences
NaSingle-groupOpen-labelTreatment

Summary

This study will evaluate the long-term safety of NBI-1117568 in adults with schizophrenia.

Timeline

Start
2025-07-11
Primary completion
2031-12
Completion
2031-12

Drugs

EvaluationDrugModalityDoseRoute
Subject NBI-1117568 Unknown — Oral

Indications

schizophrenia